Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
INFI Stock Summary
In the News
Why Is Infinity Pharmaceuticals (INFI) Stock Up 84% Today?
Infinity Pharmaceuticals (NASDAQ: INFI ) stock is rocketing higher on Tuesday morning despite a lack of news from the biopharmaceutical company. Investors seeking out news concerning shares of INFI stock this morning won't find any new press releases or filings.
MEI Pharma and Infinity Pharmaceuticals Host Video Webcast Providing Overview and Update on Pending Merger to Advance Three Promising Clinical Oncology Candidates
SAN DIEGO & CAMBRIDGE, Mass.--(BUSINESS WIRE)--MEI Pharma, Inc. (Nasdaq: MEIP) (“MEI”), a clinical-stage pharmaceutical company focused on advancing new therapies for cancer, and Infinity Pharmaceuticals, Inc. (Nasdaq: INFI) (“Infinity”), a clinical-stage biotechnology company developing eganelisib, a first-in-class, oral, immuno-oncology macrophage reprogramming drug candidate, announced today that the companies will host a recorded joint video webcast that will be available at 8:00 am Eastern.
Infinity Pharmaceuticals (INFI) Reports Q4 Loss, Lags Revenue Estimates
Infinity (INFI) delivered earnings and revenue surprises of 8.33% and 95.43%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Will Infinity Pharmaceuticals (INFI) Report Negative Q4 Earnings? What You Should Know
Infinity (INFI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Top 5 Health Care Stocks Which Could Rescue Your Portfolio This Month - Cara Therapeutics (NASDAQ:CARA), AdaptHealth (NASDAQ:AHCO)
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.
Down 44.4% in 4 Weeks, Here's Why Infinity (INFI) Looks Ripe for a Turnaround
The heavy selling pressure might have exhausted for Infinity (INFI) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
Infinity Pharmaceuticals, Inc. (INFI) Q3 2022 Earnings Call Transcript
Infinity Pharmaceuticals, Inc. (NASDAQ:INFI ) Q3 2022 Earnings Conference Call November 14, 2022 8:30 AM ET Company Participants Jayne Kauffman - Senior Executive Coordinator Adelene Perkins - Chairman and Chief Executive Officer Robert Ilaria - Chief Medical Officer Larry Bloch - President Conference Call Participants Edward Tenthoff - Piper Sandler Soumit Roy - Jones Research Mayank Mamtani - B. Riley Operator Ladies and gentlemen, thank you for standing by.
Infinity Pharmaceuticals Announces the Date of Its Third Quarter 2022 Financial Results Conference Call and Webcast
CAMBRIDGE, Mass.
Infinity Pharmaceuticals, Inc. (INFI) CEO Adelene Perkins on Q2 2022 Results - Earnings Call Transcript
Start Time: 16:30 January 1, 0000 4:58 PM ET Infinity Pharmaceuticals, Inc. (NASDAQ:INFI ) Q2 2022 Earnings Conference Call August 09, 2022, 16:30 PM ET Company Participants Adelene Perkins - Chair and CEO Robert Ilaria - CMO Larry Bloch - President Jayne Kauffman - Senior Executive Coordinator Conference Call Participants Edward Tenthoff - Piper Sandler Robyn Karnauskas - Truist Securities Operator Ladies and gentlemen, thank you for standing by. Welcome to the Infinity Pharmaceuticals Conference Call to discuss the Company's Second Quarter 2022 Financial Results and Business Update.
Infinity Pharmaceuticals to Participate in Upcoming H.C. Wainwright Global Investment Conference
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Infinity Pharmaceuticals, Inc. (NASDAQ: INFI), a clinical-stage biotechnology company developing eganelisib, a first-in-class, oral, immuno-oncology macrophage reprogramming therapeutic, today announced that management will be presenting a corporate overview and participating in 1-on-1 meetings at the upcoming H.C. Wainwright Global Investment Conference May 23-25, 2022. H.C. Wainwright Global Investment Conference Presentation (hybrid) Date: Tuesday, May 24th
INFI Financial details
INFI Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2022-12-31
Metric | History | 2018-12-31 | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 0.4 | 0.05 | 0.03 | 0.02 | 0.03 | |
Net income per share | -0.2 | -0.83 | -0.72 | -0.53 | -0.48 | |
Operating cash flow per share | -0.09 | -0.73 | -0.6 | -0.47 | -0.48 | |
Free cash flow per share | -0.09 | -0.77 | -0.6 | -0.47 | -0.48 | |
Cash per share | 1.06 | 0.74 | 0.57 | 0.94 | 0.43 | |
Book value per share | 0.95 | 0.14 | -0.38 | 0.25 | -0.21 | |
Tangible book value per share | 0.95 | 0.14 | -0.38 | 0.25 | -0.21 | |
Share holders equity per share | 0.95 | 0.14 | -0.38 | 0.25 | -0.21 | |
Interest debt per share | 0 | 0.09 | 0.43 | 0.02 | 0.01 | |
Market cap | 65.39M | 54.7M | 126.9M | 192.59M | 49.98M | |
Enterprise value | 16.77M | 34.37M | 121.79M | 113.3M | 12.58M | |
P/E ratio | -5.81 | -1.16 | -2.96 | -4.24 | -1.16 | |
Price to sales ratio | 2.95 | 17.94 | 73.82 | 103.66 | 19.27 | |
POCF ratio | -13.87 | -1.32 | -3.55 | -4.74 | -1.18 | |
PFCF ratio | -13.87 | -1.25 | -3.55 | -4.74 | -1.18 | |
P/B Ratio | 1.25 | 7.08 | -5.52 | 8.93 | -2.62 | |
PTB ratio | 1.25 | 7.08 | -5.52 | 8.93 | -2.62 | |
EV to sales | 0.76 | 11.27 | 70.85 | 60.98 | 4.85 | |
Enterprise value over EBITDA | -1.43 | -0.75 | -3.2 | -2.54 | -0.28 | |
EV to operating cash flow | -3.56 | -0.83 | -3.41 | -2.79 | -0.3 | |
EV to free cash flow | -3.56 | -0.78 | -3.4 | -2.79 | -0.3 | |
Earnings yield | -0.17 | -0.86 | -0.34 | -0.24 | -0.87 | |
Free cash flow yield | -0.07 | -0.8 | -0.28 | -0.21 | -0.85 | |
Debt to equity | 0 | 0.3 | -1.02 | 0.07 | -0.05 | |
Debt to assets | 0 | 0.05 | 0.6 | 0.02 | 0.02 | |
Net debt to EBITDA | 4.14 | 0.45 | 0.13 | 1.78 | 0.83 | |
Current ratio | 7.75 | 4.6 | 3.26 | 6.19 | 2.96 | |
Interest coverage | -128.27 | -17.82 | -15.75 | -250.46 | -249.13 | |
Income quality | 0.42 | 0.88 | 0.88 | 0.9 | 0.96 | |
Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
Payout ratio | 0 | 0 | 0 | 0 | 0 | |
Sales general and administrative to revenue | 0.64 | 4.69 | 7.22 | 7.63 | 5.19 | |
Research and developement to revenue | 0.89 | 8.89 | 15.57 | 17.03 | 12.5 | |
Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
Capex to operating cash flow | 0 | 0.06 | 0 | 0 | 0 | |
Capex to revenue | 0 | -0.76 | -0.03 | -0.01 | -0.01 | |
Capex to depreciation | 0 | -10.63 | -0.09 | -0.02 | -0.04 | |
Stock based compensation to revenue | 0.16 | 0.7 | 0.85 | 1.45 | 1.4 | |
Graham number | 2.08 | 1.59 | 2.49 | 1.73 | 1.53 | |
ROIC | -0.24 | -3.81 | -16.87 | -1.85 | 2.45 | |
Return on tangible assets | -0.19 | -0.96 | -1.09 | -0.54 | -1.03 | |
Graham Net | 0.92 | 0.02 | -0.47 | 0.2 | -0.26 | |
Working capital | 52.1M | 34.88M | 24.97M | 68.97M | 26.67M | |
Tangible asset value | 52.46M | 7.73M | -22.99M | 21.57M | -19.05M | |
Net current asset value | 52.06M | 3.29M | -26.29M | 19.05M | -20.9M | |
Invested capital | 0 | 0.3 | -1.02 | 0.07 | -0.05 | |
Average receivables | 0 | 0 | 0 | 0 | 0 | |
Average payables | 828K | 1.41M | 2.3M | 2.65M | 3.36M | |
Average inventory | 0 | 0 | 0 | 0 | 0 | |
Days sales outstanding | 0 | 0 | 0 | 0 | 0 | |
Days payables outstanding | 6.33K | 80.96 | 1.05K | 756.07 | 1.03K | |
Days of inventory on hand | 0 | 0 | 0 | 0 | 0 | |
Receivables turnover | 0 | 0 | 0 | 0 | 0 | |
Payables turnover | 0.06 | 4.51 | 0.35 | 0.48 | 0.35 | |
Inventory turnover | 0 | 0 | 0 | 0 | 0 | |
ROE | -0.21 | -6.09 | 1.87 | -2.11 | 2.27 | |
Capex per share | 0 | -0.04 | 0 | 0 | 0 |
Quarterly Fundamentals Overview
Last date of statement is 2023-06-30 for Q2
Metric | History | 2022-06-30 | 2022-09-30 | 2022-12-31 | 2023-03-31 | 2023-06-30 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | |
Net income per share | -0.13 | -0.12 | -0.1 | -0.12 | -0.11 | |
Operating cash flow per share | -0.12 | -0.11 | -0.1 | -0.14 | -0.09 | |
Free cash flow per share | -0.12 | -0.11 | -0.1 | -0.14 | -0.09 | |
Cash per share | 0.63 | 0.53 | 0.43 | 0.29 | 0.2 | |
Book value per share | -0.01 | -0.12 | -0.21 | -0.32 | -0.42 | |
Tangible book value per share | -0.01 | -0.12 | -0.21 | -0.32 | -0.42 | |
Share holders equity per share | -0.01 | -0.12 | -0.21 | -0.32 | -0.42 | |
Interest debt per share | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | |
Market cap | 56.17M | 106.38M | 49.98M | 14.31M | 18.88M | |
Enterprise value | 11.52M | 60.25M | 12.58M | -10.65M | 1.76M | |
P/E ratio | -1.17 | -2.52 | -1.42 | -0.34 | -0.47 | |
Price to sales ratio | 81.88 | 149.41 | 92.04 | 19.57 | 32.38 | |
POCF ratio | -5.3 | -11.32 | -5.62 | -1.14 | -2.36 | |
PFCF ratio | -5.3 | -11.32 | -5.63 | -1.14 | -2.36 | |
P/B Ratio | -50.74 | -9.78 | -2.62 | -0.51 | -0.5 | |
PTB ratio | -50.74 | -9.78 | -2.62 | -0.51 | -0.5 | |
EV to sales | 16.8 | 84.62 | 23.17 | -14.57 | 3.02 | |
Enterprise value over EBITDA | -0.97 | -5.59 | -1.32 | 0.93 | -0.18 | |
EV to operating cash flow | -1.09 | -6.41 | -1.41 | 0.85 | -0.22 | |
EV to free cash flow | -1.09 | -6.41 | -1.42 | 0.85 | -0.22 | |
Earnings yield | -0.21 | -0.1 | -0.18 | -0.74 | -0.53 | |
Free cash flow yield | -0.19 | -0.09 | -0.18 | -0.88 | -0.42 | |
Debt to equity | -1.07 | -0.1 | -0.05 | -0.03 | -0.02 | |
Debt to assets | 0.02 | 0.02 | 0.02 | 0.03 | 0.03 | |
Net debt to EBITDA | 3.75 | 4.28 | 3.92 | 2.19 | 1.71 | |
Current ratio | 4.16 | 3.48 | 2.96 | 2.51 | 1.65 | |
Interest coverage | -267.07 | -241.8 | -211.96 | -255.71 | -224.89 | |
Income quality | 0.88 | 0.88 | 0.96 | 1.14 | 0.8 | |
Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
Payout ratio | 0 | 0 | 0 | 0 | 0 | |
Sales general and administrative to revenue | 5.09 | 4.92 | 5.14 | 8.13 | 6.44 | |
Research and developement to revenue | 12.82 | 10.76 | 12.82 | 8.01 | 11.32 | |
Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
Capex to operating cash flow | 0 | 0 | 0 | 0 | 0 | |
Capex to revenue | 0 | 0 | 0.03 | 0 | 0 | |
Capex to depreciation | 0 | 0 | 0.16 | 0 | 0 | |
Stock based compensation to revenue | 1.19 | 1.29 | 1.88 | 2.43 | 1.47 | |
Graham number | 0.19 | 0.57 | 0.69 | 0.92 | 1.02 | |
ROIC | -9.45 | 1.22 | 0.51 | 0.41 | 0.28 | |
Return on tangible assets | -0.19 | -0.2 | -0.21 | -0.35 | -0.47 | |
Graham Net | -0.07 | -0.17 | -0.26 | -0.36 | -0.45 | |
Working capital | 45.27M | 35.15M | 26.67M | 17.07M | 7.84M | |
Tangible asset value | -1.11M | -10.87M | -19.05M | -28.32M | -37.41M | |
Net current asset value | -3.35M | -13.12M | -20.9M | -29.91M | -38.73M | |
Invested capital | -1.07 | -0.1 | -0.05 | -0.03 | -0.02 | |
Average receivables | 0 | 0 | 0 | 0 | 0 | |
Average payables | 1.91M | 1.88M | 3.18M | 3.17M | 1.72M | |
Average inventory | 0 | 0 | 0 | 0 | 0 | |
Days sales outstanding | 0 | 0 | 0 | 0 | 0 | |
Days payables outstanding | 394.13 | 409.51 | 1.21K | 394.9 | 384.03 | |
Days of inventory on hand | 0 | 0 | 0 | 0 | 0 | |
Receivables turnover | 0 | 0 | 0 | 0 | 0 | |
Payables turnover | 0.23 | 0.22 | 0.07 | 0.23 | 0.23 | |
Inventory turnover | 0 | 0 | 0 | 0 | 0 | |
ROE | 10.8 | 0.97 | 0.46 | 0.38 | 0.27 | |
Capex per share | 0 | 0 | 0 | 0 | 0 |
INFI Frequently Asked Questions
What is Infinity Pharmaceuticals, Inc. stock symbol ?
Infinity Pharmaceuticals, Inc. is a US stock , located in Cambridge of Ma and trading under the symbol INFI
What is Infinity Pharmaceuticals, Inc. stock quote today ?
Infinity Pharmaceuticals, Inc. stock price is $0.008 today.
Is Infinity Pharmaceuticals, Inc. stock public?
Yes, Infinity Pharmaceuticals, Inc. is a publicly traded company.